Eris Life Sciences Projects Revenue of ₹550-600 Crore for FY27 with EBITDA Target of ₹180-200 Crore

1 min read Updated on 21 Feb 2026, 05:19 AM

Reviewed by

Naman SScanX News Team

Overview

Eris Life Sciences has announced financial projections for FY27, targeting revenue of ₹550-600 crore and EBITDA of ₹180-200 crore. These projections reflect the pharmaceutical company's growth expectations and strategic planning framework for the upcoming fiscal year.

*this image is generated using AI for illustrative purposes only.

Eris Life Sciences has outlined its financial projections for FY27, setting clear revenue and profitability targets as part of its strategic roadmap. The pharmaceutical company has provided specific guidance on its expected financial performance for the fiscal year.

Financial Projections for FY27

The company has established comprehensive financial targets for FY27, encompassing both revenue growth and profitability metrics. These projections provide insight into the company's expected trajectory and operational efficiency improvements.

Financial Metric:	FY27 Projection
Revenue:	₹550-600 crore
EBITDA:	₹180-200 crore

Revenue and Profitability Outlook

Eris Life Sciences expects to achieve revenue in the range of ₹550-600 crore for FY27. This revenue projection indicates the company's anticipated growth across its pharmaceutical portfolio and market expansion initiatives.

The company has also set EBITDA expectations of ₹180-200 crore for FY27. This profitability target suggests the organization's focus on operational efficiency and margin improvement alongside revenue growth.

Strategic Planning Framework

These financial projections represent Eris Life Sciences' strategic planning approach for FY27. The company has established clear financial benchmarks that will guide its operational decisions and resource allocation during the fiscal year. The revenue and EBITDA targets provide a framework for measuring the company's performance against its stated objectives.